Enanta Pharmaceuticals Inc
Statements
Cash Flow
Enanta Pharmaceuticals Inc (ENTA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -10.0 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.1 | 3.1 | -3.0 | -4.8 | 57 | 4.4 | -7.6 | 4.0 | 28 | 30 | 30 | 2.5 | 8.5 | 12 | 15 | -4.5 | -15 | -15 | -4.6 | -30 | -21 | -13 | -26 | -30 | -16 | -36 | -14 | -32 | -22 | -25 | -29 | -15 | -10 | -17 | -13 | 18 | -6.5 | -12 | -7.2 | -10.0 | -35 | |
| 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | 0.5 | 0.5 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.9 | 1.2 | 1.2 | 1.3 | 1.3 | 1.2 | 1.2 | 4.9 | |
| 2.5 | 3.3 | 3.5 | 3.1 | 3.2 | 4.1 | 3.6 | 4.0 | 4.1 | 5.8 | 4.7 | 4.2 | 4.5 | 5.1 | 5.0 | 4.8 | 4.7 | 4.9 | 5.3 | 5.5 | 5.4 | 6.1 | 6.5 | 7.6 | 6.8 | 7.1 | 7.4 | 7.0 | 6.7 | 8.1 | 5.6 | 5.4 | 7.7 | 5.7 | 4.7 | 4.2 | 4.0 | 3.8 | 3.7 | 3.7 | 15 | |
| -0.6 | 1.0 | -0.6 | -0.7 | 10 | 7.0 | 5.1 | 5.1 | 0.2 | 5.0 | 4.8 | 2.7 | 1.3 | 4.8 | 1.7 | 0.9 | 19 | 3.9 | 5.1 | 3.8 | 5.6 | 6.1 | 6.1 | 7.7 | 6.8 | 7.1 | 7.3 | 7.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.3 | 6.4 | 2.2 | 3.6 | 9.8 | -15 | -26 | -22 | 0.7 | -0.4 | 22 | -6.9 | -2.8 | -6.4 | 18 | 7.7 | -6.5 | -12 | 11 | -10 | -2.9 | 9.9 | -0.1 | -6.4 | 3.4 | -14 | 17 | -1.2 | 6.2 | -1.4 | -3.3 | 2.7 | 9.2 | 0.1 | 2.1 | 32 | 5.4 | -2.9 | 0.0 | 2.5 | 5.0 | |
| 0.4 | 1.0 | 0.6 | 0.7 | 0.2 | 0.5 | 0.8 | 1.1 | 0.6 | 0.4 | 2.5 | 2.2 | 0.3 | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 0.1 | 0.4 | 0.0 | 0.4 | 0.1 | 0.3 | 1.4 | 3.2 | 2.4 | 2.2 | 1.4 | 0.8 | 1.7 | 6.5 | 9.0 | 8.7 | 2.5 | 0.2 | 1.5 | 0.1 | 0.0 | 0.0 | 1.6 | |
| -6.1 | 0.9 | 1.8 | 7.7 | -15 | -2.4 | 6.5 | -31 | -7.9 | -21 | 1.3 | -15 | -52 | -37 | 28 | 27 | 2.5 | -17 | 25 | -44 | 73 | 46 | -35 | 16 | 28 | 34 | 47 | -146 | 12 | -13 | 59 | -6.3 | 19 | 69 | -4.4 | -26 | 2.3 | -47 | 12 | 14 | -19 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.0 | -0.2 | 0.2 | 0.8 | 0.4 | -1.8 | 3.0 | 0.0 | 1.2 | -4.2 | 0.5 | 6.8 | -1.1 | 4.7 | -1.5 | 0.2 | 0.8 | 1.2 | -0.5 | 0.9 | 10 | 3.8 | 4.1 | 0.0 | -0.8 | -2.9 | – | 0.0 | -0.2 | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.3 | -4.9 | – | – | – | -5.9 | – | – | – | |
| 0.1 | 0.0 | -0.2 | 0.2 | 1.0 | 0.4 | 0.0 | 3.0 | 1.0 | 1.1 | 0.3 | 0.5 | 0.7 | 1.2 | 4.4 | 3.2 | 0.2 | 0.3 | 1.2 | 0.7 | 0.9 | 9.6 | 3.4 | 4.1 | 2.9 | 0.3 | -2.0 | 200 | 0.0 | -7.4 | -6.4 | -6.6 | -7.2 | -5.0 | -6.9 | -6.4 | -8.3 | 64 | -7.3 | -5.5 | 43 | |
| -8.2 | 4.0 | -1.4 | 3.1 | 43 | 2.4 | -1.1 | -24 | 21 | 10 | 32 | -12 | -43 | -24 | 47 | 26 | -13 | -32 | 22 | -73 | 53 | 42 | -58 | -9.3 | 16 | -1.8 | 31 | 22 | -9.8 | -45 | 24 | -28 | 1.5 | 47 | -25 | -15 | -13 | 5.1 | -2.5 | -1.5 | -11 | |
| -2.5 | 2.2 | -3.6 | -5.5 | 57 | 3.9 | -8.3 | 2.9 | 28 | 30 | 28 | 0.3 | 8.2 | 12 | 14 | -4.8 | -16 | -15 | -4.7 | -30 | -21 | -14 | -26 | -30 | -17 | -39 | -16 | -34 | -23 | -26 | -30 | -21 | -19 | -26 | -16 | 17 | -7.9 | -12 | -7.2 | -10.0 | -37 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.